Seymour J F, Estey E H
Department of Clinical Haematology and Medical Oncology, Royal Melbourne Hospital, Melbourne, Australia.
Leuk Lymphoma. 1995 Mar;17(1-2):79-85. doi: 10.3109/10428199509051706.
Auer rods were first recognized at the beginning of this century. Their presence soon became considered to be an unequivocal manifestation of a leukemic process. Possibly influenced by this long-held assumption, in 1982 the French-American-British co-operative group (FAB) incorporated the presence of Auer rods into a classification system of the myelodysplastic syndromes that remains in widespread clinical usage today. Although unsubstantiated at the time, the presence of Auer rods was suggested to indicate a rapidly progressive disorder and a poor prognosis. In the absence of studies confirming the utility of Auer rods as a diagnostic criterion, the FAB classification system of myelodysplastic syndromes has been widely used to allocate therapy. In this review we examine the early descriptions of Auer rods and critically evaluate the studies examining the value their presence has in the classification and prognosis of patients with myelodysplastic syndromes.
奥厄小体于本世纪初首次被发现。它们的存在很快被认为是白血病过程的明确表现。可能受这一长期以来的假设影响,1982年,法美英合作组(FAB)将奥厄小体的存在纳入骨髓增生异常综合征的分类系统,该系统至今仍在临床广泛应用。尽管当时没有确凿证据,但奥厄小体的存在被认为表明病情进展迅速且预后不良。由于缺乏证实奥厄小体作为诊断标准效用的研究,FAB骨髓增生异常综合征分类系统已被广泛用于指导治疗。在本综述中,我们研究了奥厄小体的早期描述,并批判性地评估了关于其存在在骨髓增生异常综合征患者分类和预后方面价值的研究。